Papzimeos
-
FDA grants accelerated approval to a DNA immunotherapy for recurrent airway papillomas
The US Food and Drug Administration granted accelerated approval on 30 October 2026 to Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd, Inovio Pharmaceuticals) for adults with…